RxDoctor Payments Data

Michael Hackman

Psychiatry · Huntington, WVNPI 1013150945

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $13,800 of the $18,063 with a category attached, or 76.4%. AbbVie accounts for 93.1% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2023 at $9,390 and has fallen 93.0% since, to $659 in 2025. Among psychiatry clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,063in general payments, 2019–2025

Across 179 payments — averaging $100.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$17K
  • Otsuka America Pharmaceutical, Inc.$353
  • Axsome Therapeutics, Inc.$293
  • Takeda Pharmaceuticals U.S.A., Inc.$167
  • Sunovion Pharmaceuticals Inc.$102
  • Lundbeck LLC$92
  • plus $247 from 8 others

What the payments were for

  • Speaking & faculty fees$13,80076%
  • Travel & lodging$1,4888%
  • Food & beverage$2,77515%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,063 in reported general payments places this provider in the 90th percentile of 177 psychiatry providers in West Virginia.

See all psychiatry providers in West Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole15$33,519
CaplytaLumateperone Tosylate20$32,698
SuboxoneBuprenorphine Hcl/Naloxone Hcl60$24,485
VraylarCariprazine Hcl17$23,787
Chlorpromazine Hcl27$17,417
Aripiprazole104$12,153
Divalproex Sodium112$9,602
Oxcarbazepine84$6,215
BelsomraSuvorexant14$5,945
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl35$4,790
Risperidone199$4,213
Buspirone Hcl148$3,698
Trazodone Hcl250$3,024
Quetiapine Fumarate114$2,559
Sertraline Hcl240$2,475

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$353$33,51915 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$44$32,69820 claims
AbbVieVraylar$16,808$23,78717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 177 psychiatry providers in West Virginia.

Other psychiatry in Huntington

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →